|
|
Volumn 3, Issue 2, 2012, Pages 199-212
|
|
Diaryl urea LDV peptidomimetics as α 4β 1 integrin antagonists: Synthesis, adhesion inhibition and toxicity evaluation on CCRF-CEM cell line
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 PHENYLETHYL 3 [2 (2 TERT BUTOXY 2 OXOETHOXY) 5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOATE;
3 [2 (2 TERT BUTOXY 2 OXOETHOXY) 5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOIC ACID;
3 [2 (2 TERT BUTOXY 2 OXOETHOXY) 5 [[[4 [[[2 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOATE;
3 [2 HYDROXY 5 [[[4 [[[2 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOIC ACID;
3 [5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO] 2 HYDROXYPHENYL]PROPANOIC ACID;
3[2 (CARBOXYMETHOXY) 5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOIC ACID;
4 CHLOROBENZYL 3 [2 (2 TERT BUTOXY 2 OXOETHOXY) 5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOATE;
[2 [3 (BENZYLAMINO) 3 OXOPROPYL] 4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENOXY]ACETIC ACID;
[2 [3 (BENZYLOXY) 3 OXOPROPYL] 4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENOXY]ACETIC ACID;
[2 [3 (BENZYLOXY) 3 OXOPROPYL] 4 [[[4 [[[2 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENOXY]ACETIC ACID;
[2 [3 [(4 CHLOROBENZYL)OXYL] 3 OXOPROPYL] 4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENOXY]ACETIC ACID;
[4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO] 2 [3 OXO 3 (2 PHENYLETHOXY)PROPYL]PHENOXY]ACETIC ACID;
[4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO] 2 [3 OXO 3 [(2 PHENYLETHYL)AMINO]PROPYL]PHENOXY]ACETIC ACID;
BENZYL 3 [2 (2 TERT BUTOXY 2 OXOETHOXY) 5 [[[4 [[[2 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOATE;
BENZYL 3 [2 HYDROXY 5 [[[4 [[[2 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOATE;
BENZYL 3 [5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO] 2 HYDROXYPHENYL]PROPANOATE;
DIARYLUREA LEUCYLASPARTYLVALYL PEPTIDOMIMETIC;
FIBRONECTIN;
METHYL 3 [2 HYDROXY 5 [[[4 [[[2 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENYL]PROPANOATE;
METHYL 3 [5 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO] 2 HYDROXYPHENYL]PROPANOATE;
PEPTIDOMIMETIC AGENT;
TERT BUTYL[2 [3 (BENZYLAMINO) 3 OXOPROPYL] 4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENOXY]ACETATE;
TERT BUTYL[4 [[[4 [[(2,6 DIMETHYLPHENYL)CARBAMOYL]AMINO]PHENYL]ACETYL]AMINO]PHENOXY]ACETATE;
UNCLASSIFIED DRUG;
VERY LATE ACTIVATION ANTIGEN 4;
ARTICLE;
CELL ADHESION;
CELL ASSAY;
CELL DETACHMENT ASSAY;
CELL LINE;
CHEMICAL MODIFICATION;
CONCENTRATION RESPONSE;
CONTROLLED STUDY;
DEPROTECTION REACTION;
DRUG ACTIVITY;
DRUG DESIGN;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ESTERIFICATION;
HUMAN;
HUMAN CELL;
HYDROGENATION;
IC 50;
PEPTIDE SYNTHESIS;
PRIORITY JOURNAL;
PROTEIN MOTIF;
|
|
EID: 84857287163
PISSN: 20402503
EISSN: 20402511
Source Type: Journal
DOI: 10.1039/c1md00229e Document Type: Article |
|
Times cited : (5)
|
|
References (38)
|
